Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Oriola-KD Oyj, Q1'24

By Inderes4/25/2024, 7:00 AM
Oriola

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Timo
00:02 - 01:26

Good morning, everyone, and a warm welcome to the Oriola Q1 results webcast. I am Douglas Dennison from Oriola Investor Relations. With me today, I have our CEO, Katerina Gabrielsson, and CFO, Tomas Rupšys. First, a note about the change in our reporting. As of January, we have two reporting segments instead of the one that we had before. The two segments are distribution and wholesale, and we published the comparative figures for the segments in March. The Q1 report has been prepared according to the new reporting structure. And after the presentation, we will open up for your questions and you can send them to us already, uh, during the presentation. As a reminder, in the Q&A, we will focus on questions relating to Oriola's business and financial development. Uh, we can answer questions on Kronans Apotek and Svensk dos AB, but only within a limited scope. Finally, please remember that we are recording this webcast and the On-Demand version will be published on our website. Before handing over to Katerina. Here is the customary disclaimer that we all should be aware of. And now, without further ado, Katarina, please go ahead.

Katerina Gabrielsson
01:26 - 09:42

Thank you, Douglas. Good morning and welcome everyone also on my behalf. We will start today with quarter one highlights and a couple of comments on the operating environment and market. And then I will end my part with a review of the segments. And after this, Tomas will take over, take you through the financials before we continue with the Q&A. To begin with, I believe that we can say that we had a good start to the year. In quarter one, the sales grew by 4% to €375 million. This was driven by both distribution and wholesale segments. Usually, here we would comment on the constant currency figures, but in quarter one, the Swedish krona did not cause any significant head or tailwind year on year. So we will focus on the reported figures. Also, profitability improved in quarter one. Adjusted EBIT, when excluding the loss from the Swedish dose dispensing business, improved by 14% to €4.5 million, while the reported adjusted EBIT was 4 million. The improvement in profitability was supported by lower operating expenses and freight costs. A brief comment about the refined strategy that we launched at the end of last year. The implementation is progressing well and a key milestone was, of course, the announcement of the ERP and warehouse management investments in January. This project is well up to speed and proceeding according to plan. But I also wanted to comment that we are focusing a lot this year on engaging with our senior management. This is an essential part of rolling out the strategy so that we ensure alignment and strengthen our common understanding of our priorities, but also importantly, develop our leadership. And then finally, a couple of comments on the joint venture company Kronans Apotek. Apotekstjänst Sverige AB. In quarter one, e-commerce continued to grow steadily while the customer flow in the brick-and-mortar pharmacies was weaker year on year, which resulted in reduced volumes, market share, and adjusted EBIT. And you might have seen last week that we announced regarding Kronans Apotek. But let me recap if you haven't seen it. Last week, Kronans Apotek got a new CEO. The previous CEO, Tomas Rupšys, did an important job with the integration of Kronans Apotek and Apotekstjänst Sverige AB. But now it's time for the company to go into the next phase of its development. Kronans Apotek will continue to develop its customer experience and end product range, both in physical and digital stores. The focus remains on long-term profitability improvement, integration activities, and business development. For this role, the board has appointed Tomas Rupšys, who has vast experience in retail and fast-moving consumer goods both in the UK and in Ireland, and he has also been the CEO of Maxima, the biggest retail chain in Lithuania. When looking at the overall operating environment, we saw slight stabilization compared with last year. Cost inflation has slowed down, and energy prices have been stabilizing while we saw fluctuations in the fuel prices. Although the consumer confidence indicators, both in Sweden and in Finland, have slightly improved from the earlier significant drop. They have still been below historical averages. So all in all, consumer confidence is still weak. The pharmaceutical distribution market continued at a steady growth in quarter one. Still, the challenges in the availability of pharmaceuticals have continued in Europe. Since we now have two new reporting segments, we also want to provide some additional market information relating to the wholesale segment. But first, if we look at the pharmaceutical distribution market, we saw that the market value in Sweden grew by 7% in the first quarter and by 4% in Finland. Our market shares were stable year on year, with a share of 42% in Sweden and 45% in Finland. In the Finnish dose dispensing business, we had a market share of 29%. With regards to the consumer health market, we want to give you some indication of market size and growth. While we will not comment on the market development on a quarterly basis based on external market data, the value of the market is estimated at around €1.5 billion. The historical growth has been about 3%, and that is expected to continue, although with significant differences between the categories. In Sweden, for example, products such as vitamins, dietary supplements, and sports nutrition are expected to see increased demand, while in Finland consumers are expected to demand more natural and clean products with high-quality ingredients and available in easy-to-use formats. And then before I dive into the segments, I want to make a brief reminder of what the segments include. We changed the reporting at the beginning of this year so that we can be more transparent and also give better visibility into our businesses. The distribution segment consists of pharmaceutical, logistics, and dose dispensing services. This is the largest segment that we have with an annual net sales of €1.2 billion, which equals about 79% of the group net sales. The wholesale segment consists of the wholesale of traded goods and over-the-counter or OTC products, parallel import, and special licensed medicines, as well as advisory services. The annual net sales of the segment are about €306 million. The wholesale business is a bit more profitable because of the type of products and services that we sell in this segment, and that is also what you can see in this picture. Next, I will discuss the segments in quarter one and also start off with the dose dispensing segment. In quarter one, the net sales grew by 4% to €294 million. This was largely driven by steady market growth. Profitability improved by 29%, with adjusted EBIT increasing to €4.1 million. When we exclude losses from the Swedish dose dispensing business, adjusted EBIT was €4.6 million, which is €1 million above quarter one last year. Profitability improvement was important, supported by a lower cost base compared with the previous year. Freight costs were lower thanks to operational improvements, and lower fuel prices, and operating expenses were lower due to cost reductions in the Swedish dose dispensing business. In the distribution business, we focus on our core and continue to build on the good development we saw last year. In quarter one, our market shares were stable year on year, as you saw earlier, and we have gained new customers and renewed important distribution contracts to support our growth going forward. Then looking at the wholesale segments. In quarter one, the net sales grew by 5% to €81 million. We saw solid growth in the Swedish wholesale business and also good development in advisory services. Profitability, on the other hand, declined slightly from €3 million to €2.8 million. The decline was related to low volumes in the Finnish wholesale business. Going back to our refined strategy, growing the wholesale business is one of the three strategic goals that we have in the strategy. In the long term, we want to grow the business by developing our brand portfolio and product categories. And this is something that will take some time. During the start of this year, our focus has been on building our offering and technical capabilities to better meet the needs of our growing customer segments. In addition, we have made appointments in key leadership positions, so really building a solid foundation for growth is what we have started to do. Now, Tomas, let's go over to you and look at the financials.

Tomas Rupšys
09:44 - 19:09

Thank you, Katarina, and good morning from me as well. As Katarina said in her opening words, we had a good start to the year, with solid growth on the top line and good profitability improvement as well. Invoicing increased by 6% to €908 million because there was no significant headwind or tailwind in the Swedish krona in Q1. I will not specifically comment on the constant currency figures. On net sales, we saw solid growth of 4%, ending at €375 million. Invoicing and net sales growth was driven by the pharmaceutical distribution and wholesale segments. Adjusted EBIT increased from €3.5 million to €4 million, and when we exclude the losses from the Swedish dose dispensing business, we see an adjusted EBIT of €4.5 million compared to €3.9 million in Q1 last year. And then let's look at net sales and EBIT which is on net sales. The growth is largely driven by the distribution segment, where growth was €17.6 million. In wholesale, net sales grew by €3.6 million, which is also positive considering the smaller size of the segment. Group items on net sales are not significant. While the Swedish dispensing business contributed positively to net sales by €3 million. This gives a total of €375 million in net sales on a bit. On the EBIT side, we also see the contribution by distribution, with EBIT improved by €1 million and offsetting the decline we see in wholesale and group items. Excluding the loss of €0.5 million from Swedish dose dispensing business, adjusted EBIT was €4.5 million. And then, just to remind that we have started at the beginning of this year, a big ERP project where actually we are taking the system into use starting from 2026 and continuing to 2027 as well. And costs related to that ERP project, recognized in the income statement during the first quarter were in total €0.7 million, and most of these were allocated to the group items. And I said so it's not in that in that sense to our current operative work and the benefits are coming late. Overall profitability improvement was supported by lower operating expenses and freight costs. The decrease in freight costs was related to operational improvement and lower fuel prices. And now moving on to the profit for the period. In Q1, profit for the period was -€2.3 million, hence earnings per share were negative at €0.01 per share. We had adjusted items of €0.3 million in Q1, and they were related to the sale of the dose dispensing business in Sweden. There are two main drivers for the profit development: the loss from Kronans Apotek and increasing net financial expenses. In Q1, we recognized a loss of €3.5 million from Kronans Apotek, compared to the loss of €0.5 million in Q1 last year. As we know, the interest rates increased significantly last year and in Q1, our net financial expenses increased year on year from €1.5 million to €2.2 million. Although our debt level has decreased, so a decline in the profit for the period compared to Q1 last year. Then looking at the cash flow. Net cash flow from operating activities in Q1 was -€11.3 million. Of these, changes in the working capital accounted for -€15.4 million. And just to remind that it's very typical in our industry that the working capital fluctuates strongly from quarter to quarter in Q1, increase in inventories and decrease in trade payables have impacted working capital negatively. When we look at change in the cash from the end of the year, net cash flow from operating activities was -€11.3 million, from investing activities, -€0.7 million, and from financing activities -€16.6 million. The change in financing activities cash flow reflects repayments of debt and commercial papers. At the end of the period, we had 25, sorry, €29 million less in commercial papers compared with the end of the period Q1 last year. All in all, the cash position is strong, with cash and cash equivalents at €110 million at the end of the period. In Q1, we have continued to strengthen our balance sheet by lowering our debt level. We have repaid loans and issued less commercial paper, and the amount of lease liabilities has also decreased year on year. Following this, our interest-bearing debt was down €40 million from Q1 last year, and at the end of the period, our interest-bearing debt amounted to €100 million, compared to €138 million at the end of the Q1 last year. Cash and cash equivalents amounted to €110 million. This gives a negative net debt position and a gearing of -6.2%. The amount of short-term receivables at the end of the period was 93 million, which is somewhat lower than the previous year's level, but still at the current average level. To summarize, I want to say that we have a strong financial position with good cash flow and gearing on the negative side. Equity ratio has declined from 22.8 to 17.3, but is stable compared to the previous quarters. Then move on to shortly comment on Kronans Apotek uptake. In current and supportive economies, steady growth has continued, while the challenges have been more related to weak customer flows in physical pharmacies. This has resulted in lower volumes and a decline in the market, as well as adjusted EBIT. Adjusted EBIT declined from €0 to -€5.5 million in Q1. Realized synergies in Corona support. There were €3.6 million in net sales, and one-off costs related to integration amounted to €1.6 million. And for Q1, we have recognized a loss of €3.5 million in the consolidated statement of comprehensive income. Kronans Apotek remains an important strategic partner for Oriola Corporation. I will actively support Oriola Corporation in value creation as a major shareholder, and in Oriola Corporation, full profit potential is expected to materialize by the end of 2025. And then coming to the sales growth update. So, nothing new to comment on relating to that one. As we are not the divestment. In October last year, in January, we informed that the Swedish Competition Authority decided to move the investigation into phase two, and we are still waiting for a decision, but expect to get it during Q2 of this year. Then, coming at last to our guidance. And I said, so we are expecting our guidance on the outlook to remain unchanged. We expect adjusted EBIT, excluding the dose dispensing business in Sweden, for the year 2024 to increase from the adjusted EBIT for 2023, which was €19.5 million. As a key assumption, we expect the pharmaceutical distribution market to continue to grow. However, a continuation of the fragile consumer confidence might impact the wholesale market development. Additionally, the inflationary environment and related cost pressures may impact profitability. And with this, I'm ready to hand it back to Katarina.

Katerina Gabrielsson
19:11 - 19:58

Thank you, Timo. Before we take your questions, I want to summarize with the three key takeaways. Net sales grew and profitability improved year on year, which I'm very pleased about. And we saw positive development in both segments, but especially in distribution, which improved financial performance. And it did it really well. We have a solid financial position and have strengthened the balance sheet by significantly decreasing our interest-bearing debt. And last but not least, with our refined strategy, we have a clear direction forward and a good understanding of our goals and shared priorities. And with this, we are ready for questions. So let's see if the two of you have got something. And please, Timo.

Timo
19:59 - 20:39

Okay, great. So thank you, Katarina and Timo, for your presentations. We have a couple of questions in the chat already. But as a reminder to everyone, please keep them on, keep sending them to us, and we will take them. And of course, as I said earlier, we will first focus on Oriola Corporation's business development and financial performance and then take some questions on Kronans Apotek. I would take it if there is something. So let's start with the first question. So the first question goes to Timo. So, what do you consider as the minimum level of cash in the bank?

Tomas Rupšys
20:41 - 21:03

Well, if seeing the same on the kind of end of the month. Of course, we are kind of following it day to day, inside the month as well. So basically, somewhere around 60 to 70 million might be kind of the level where it should be at the lowest at month-end.

Timo
21:03 - 21:05

So, all right.

Katerina Gabrielsson
21:05 - 21:06

With this size of business.

Tomas Rupšys
21:06 - 21:08

Yes, of course. Yeah.

Timo
21:09 - 21:16

And then, what is the average maturity of short-term interest-bearing debt in months?

Tomas Rupšys
21:17 - 21:46

So maturity is sort of commercial. Papers are of course short-term, with maturities ranging from 1 to 6 months. In that sense, I'm basically saying, on our balance sheet. So there is one loan that is maturing in June, and we are thinking of paying it off. And then there is one loan that is maturing in December. And that's what we are going to negotiate.

Timo
21:46 - 22:06

Okay. Then we have a question. About ERP, do you expect ERP costs to remain at the level of €0.7 million in each quarter income in coming years, 2024 to 2026?

Unknown
22:06 - 22:09

Uh, well, it, uh, a little.

Tomas Rupšys
22:09 - 22:45

Bit fluctuations depend on what phase we are in and what we are actually doing in an ERP project, because that's actually how the IFRS rules are applied. So it depends on what kind of system you are building. And we have kind of different, uh, 30 different businesses that are kind of attached to each other. So basically, this level is probably what we are going to see at least during this year. But having said that, we have decided to be open in all aspects of our interim report. So, how much are we spending on this?

Timo
22:46 - 23:24

Okay. Thank you, Timo. So, at the moment, there are no more questions in the chat, but let's wait for a few seconds because we know there is a small, uh, lag between the live feed and us here in the studio. But it seems that there are no more questions. So, everything was clear for today. So, thank you everyone for joining us today. And the next report is coming out on the 18th of July. So, see you then, if not before that.

Unknown
23:25 - 23:25

Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…